Literature DB >> 12430182

No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese.

Nobuyuki Hamajima1, Keitaro Matsuo, Takashi Suzuki, Tsuneya Nakamura, Akira Matsuura, Shunzo Hatooka, Masayuki Shinoda, Yasuhiro Kodera, Yoshitaka Yamamura, Takashi Hirai, Tomoyuki Kato, Kazuo Tajima.   

Abstract

A case-control study was conducted to examine the possible association between digestive tract cancers and p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms in Japanese. Cases were 102 esophageal cancer patients, 144 stomach cancer patients, and 147 colorectal cancer patients, and controls were 241 non-cancer outpatients. The genotype frequencies among controls were 55.3% for p73 GG at position 4, 40.4% for GA, and 4.3% for AA, and 37.7% for p53 ArgArg, 44.4% for ArgPro, and 18.0% for ProPro. No significant differences in the genotype frequencies were observed between the controls and each case group or cases as a whole.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12430182     DOI: 10.1016/s0304-3835(02)00041-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

1.  Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients.

Authors:  Amira Toumi Arfaoui; Lilia Ben Mahmoud Kriaa; Olfa El Amine El Hadj; Majid A Ben Hmida; Myriam Khiari; T Khalfallah; Lasaad Gharbi; Sabeh Mzabi; Sadaa Bouraoui
Journal:  Virchows Arch       Date:  2010-07-20       Impact factor: 4.064

2.  Association of p73 G4C14-A4T14 polymorphisms with genetic susceptibilities to breast cancer: a case-control study.

Authors:  Xin Zhou; Chengyi Wu
Journal:  Med Oncol       Date:  2012-04-26       Impact factor: 3.064

3.  p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population.

Authors:  Hye-Rim Song; Sun-Seog Kweon; Hee Nam Kim; Jin-Mei Piao; Woo-Jun Yun; Jin-Su Choi; Jun-Eul Hwang; Ju-Young Yoon; Hyeong-Rok Kim; Young-Kyu Park; Soo-Hyun Kim; Yoo-Duk Choi; Min-Ho Shin
Journal:  Gastric Cancer       Date:  2011-04-02       Impact factor: 7.370

Review 4.  Impact of p73 gene polymorphism on cancer susceptibility: a meta analysis.

Authors:  Yixuan Liu; Weiwei Dong; Quan Mou; Yuxin Leng; Lu Zhang; Liping Duan
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China.

Authors:  Zhu Ke-Xiang; Li Yu-Min; Li Xun; Zhou Wen-Ce; Shan Yong; Liu Tao
Journal:  Mol Biol Rep       Date:  2011-05-12       Impact factor: 2.316

6.  Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study.

Authors:  Yuxing Zhang; Li Liu; Yingchun Tang; Chao Chen; Qian Wang; Jun Xu; Chao Yang; Xiaoping Miao; Sheng Wei; Jigui Chen; Shaofa Nie
Journal:  Mol Biol Rep       Date:  2012-06-29       Impact factor: 2.316

7.  Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population.

Authors:  Meenakshi Umar; Rohit Upadhyay; Rohini Khurana; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

8.  Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk.

Authors:  Lan Wang; Rui Gao; Long Yu
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

9.  Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population.

Authors:  Benyuan Deng; Fei Liu; Yonggang Wei; Limei Luo; Xi Chen; Lvnan Yan; Bo Li
Journal:  Tumour Biol       Date:  2012-10-12

10.  p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China.

Authors:  Xin Zhou
Journal:  Med Oncol       Date:  2013-02-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.